dapagliflozin

The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted…

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalisation for heart failure in adults with…

Results were presented at European Society of Cardiology Congress 2022, and published in 'New England Journal of Medicine'

Reduces risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

Forxiga is the first-ever approved medicine for the treatment of the disease in Japan

Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016,…

In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…

The drug comes in two strengths ZUCAPRIDE–M 500 priced at Rs12.80 per tablet and ZUCAPRIDE–M 1000 at Rs 14.80

Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further…

The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV)…